Anthropic launched Claude Science on July 15, 2026, a standalone AI workbench for scientists that gives paid subscribers access to an agent with more than 60 curated skills spanning cheminformatics, protein structure prediction, and single-cell RNA sequencing. The move signals a deepening commitment to life sciences; the company will also use the platform to pursue its own drug development programs for rare and neglected diseases.
The launch builds on Claude for Life Sciences, a suite of plug-ins released in October 2025 that connected Anthropic's language model to scientific research platforms. Claude Science is a dedicated product, sitting alongside the company's Claude Code and Claude Cowork offerings, and reflects an AI for Healthcare strategy that Anthropic has been reinforcing through in-house wet labs and biotech acquisitions.
From plug-ins to a standalone product
Anthropic has been building its own specialised wet labs and acquiring biotech companies to bring practical drug development expertise in-house. Eric Kauderer-Abrams, Head of Life Sciences at Anthropic, said, "We're doing this because we believe first and foremost that to build the right models, products and tools to accelerate the industry, we need to live it along with all of you. We believe in the power of tight feedback loops, and there's no substitute for having our own experiences alongside you all in the trenches trying to develop drugs."
Early adopters report faster target identification
Test users have applied Claude Science to speed up single-cell RNA sequencing, design CRISPR screens, predict protein structures, and perform cheminformatics analyses. The platform helps identify promising drug targets, automate literature reviews that once consumed years, and cut genomic analysis times. Emmanuel Frenehard, Chief Digital Officer at Sanofi, said, "Claude, paired with internal knowledge libraries, is integral to Sanofi's AI transformation. We're seeing efficiency gains across the value-chain, while our enterprise deployment has enhanced how teams work. This collaboration with Anthropic augments human expertise to deliver life-changing medicines faster to patients worldwide."
Big tech's push into AI-powered science
Claude Science enters a growing field of AI for Science & Research, where companies like Microsoft, Google DeepMind, and NVIDIA already offer platforms such as Microsoft Discovery and BioNeMo to compress R&D timelines. However, Claude Science is one of the first dedicated life sciences products released by a general-purpose frontier AI company that is open for public use.
Why this matters for science and research professionals
For researchers, Claude Science bundles over 60 specialised skills - from pathway analysis to regulatory submission support - into a single interface that can cut weeks of manual work. Because Anthropic is using the same tool internally for its own rare disease programs, the platform is likely to evolve based on real lab feedback rather than hypothetical use cases. The availability of a dedicated AI workbench from a frontier model developer signals that large language models are moving beyond general-purpose assistants and into the hands of scientists who need domain-specific tools to speed therapeutic discovery.
Your membership also unlocks:
